1. Anguilla Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Rhino Biotech Limited

Rhino Biotech Limited

RBRXF
Rhino Biotech LimitedUS flagOther OTC
0.00
USD
+0.00
- -
3,105.00Market Cap
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.02
0.01
-0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.07
Free Cash Flow per Basic Share
-0.01
-0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.25
-0.27
-0.24
-0.26
-0.22
-0.2
-0.2
-0.2
-0.21
-0.21
-0.21
-0.21
- -
-0.26
Tangible Book Value per Share
0.01
-0.01
0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.03
Basic Weighted Avg Shares
24
24
26
26
32
35
35
35
35
35
35
35
- -
21
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
- -
-1
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
Return on Invested Capital (%)
- -
- -
-331.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'07
Sep'07
Dec'07
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
24
Market Capitalization
11
7
3

Working Capital

FRC

•

in mil. unless spec.
Jun'07
Sep'07
Dec'07
Total Current Assets
- -
1
1
Cash, Cash Equivalents & STI
- -
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.27%
53.98%
54.33%
Free Cash Flow
-25.89%
-10.35%
-22.6%
Net Income, GAAP
-66.03%
-2.36%
3.97%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Nicholas W. Baxter
Full Time Employees
1
Sector
Financial Services
Industry
Shell Companies
Address
294 Heywood House South Hill Anguilla
IPO Date
Feb 4, 2005
CIK
0001278465
Website
ir.rhinobiotech.com
Similar Companies
Andretti Acquisition Corp. (WNNR-UN)
Crown Proptech Acquisitions (CPTK)
Metal Sky Star Acquisition Corporation (MSSAU)
Fortistar Sustainable Solutions Corp. (FSSIU)
Murphy Canyon Acquisition Corp. (MURF)
Ackrell SPAC Partners I Co. (ACKIU)
Business
Rhino Biotech Limited (OTC:RBRXF) develops plant- and fungi-derived nutraceuticals and biopharmaceuticals for preventative and curative applications in health and wellness. The company operates through three primary divisions: Fortify RX, which produces, manufactures, and distributes cannabis-derived cannabinoids and natural compounds for nutraceuticals, pharmaceuticals, and health products; AGRITECH RHINO (formerly Artesian Valley Agritech), which improves plant and fungus genetics via cloning and hybridization technologies, including proprietary Cannabis Sativa L. strains such as "Chiron" yielding up to 18.1% CBG with minimal THC; and BioOrganics, which conducts research and development focused on preventing contamination, deterioration, and extending the lifespan and efficacy of organic compounds sourced from plants, fungi, and microorganisms. These offerings target nutraceutical, biopharmaceutical, and agritech markets, with products including cannabinoid isolates, proprietary formulations for health fortification, and genetics for medical research. In recent developments, Rhino Biotech acquired Colorado-based Artesian Valley Farms, LLC (dba Artesian Valley Agritech) for $14.5 million in shares and $3.4 million in financing, along with Nevada-based JRD Ventures, LLC for $3.1 million in shares to secure related intellectual property, and Ohio-based Rhino Biotech, Inc. for $10 million in shares, totaling approximately $22.5 million in transactions completed in 2021 and 2022 to vertically integrate its biotech operations. The company, formerly known as Eurasia Energy Limited, underwent a name change in September 2021 and appointed a new interim board of directors in February 2022 to drive rapid growth. Recent notices issued in February 2025 indicate ongoing shareholder communications amid strategic initiatives. Founded in 2003 and headquartered at 294 Heywood House, South Hill, Anguilla, Rhino Biotech employs a small team of three and maintains mailing operations in Longmont, Colorado, with a focus on global agritech, biotech, and biopharma segments.